Combined pharmacotherapy including GLP-1 drugs produced synergistic-like decreases in alcohol intake, supporting multi-target approaches to alcohol use disorder.
Key findingCombined pharmacotherapy including GLP-1 drugs produced synergistic-like decreases in alcohol intake
What the researchers found
Combined pharmacotherapy including GLP-1 drugs produced synergistic-like decreases in alcohol intake, supporting multi-target approaches to alcohol use disorder.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Synergistic-like effect observed — combined drug effect exceeded the expected additive effect of individual treatments.
How the study worked
In publication.
Who was studied
Male rats in alcohol consumption models
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Synergistic-like decreases in alcohol intake following combined pharmacotherapy with GLP-1 and amylin in male rats.
British journal of pharmacology, 182(6), 1292-1305
Citation
Aranäs, Cajsa; Caffrey, Antonia; Edvardsson, Christian E; Vestlund, Jesper; Schmidt, Heath D; Jerlhag, Elisabet. (2025). Synergistic-like decreases in alcohol intake following combined pharmacotherapy with GLP-1 and amylin in male rats.. British journal of pharmacology, 182(6), 1292-1305. https://doi.org/10.1111/bph.17406